Eli Lilly Gains as Medicare, Medicaid Expand GLP-1 Drug Coverage
Eli Lilly secured extended Medicare and Medicaid coverage for its GLP-1 weight-loss drugs under a new government agreement, easing pricing concerns and creating a major market opportunity. Its shares closed at $1,036.05 on February 17, valuing the company at approximately $977.4 billion and offsetting a 3.9% one-month decline.
1. Government Agreement and Coverage Expansion
Under a new pact with the federal government, Eli Lilly extended Medicare and Medicaid coverage for its GLP-1 weight-loss medications. The deal addresses pricing concerns by lowering patient costs and opens millions of beneficiaries to drugs like tirzepatide, positioning Lilly to capture a significant new revenue stream.
2. Stock Reaction and Valuation
Lilly shares closed at $1,036.05 on February 17, giving the company a market capitalization near $977.4 billion, despite a 3.9% one-month share decline. Analysts cite the expanded coverage as a catalyst likely to stabilize pricing outlook and support broader investor confidence.
3. Fund Inclusion Highlights Sustainability Strategy
An investor letter from Impax US Sustainable Economy Fund included Lilly, praising the company’s innovation in healthcare access and sustainability. The fund’s annual Institutional Class return reached 16.00% in 2025, with Lilly’s GLP-1 franchise driving notable stock-specific gains against a volatile benchmark.